119 F. Supp. 3d 1213
C.D. Cal.2015Background
- ScripsAmerica (Scrips), an OTC-traded pharmaceutical distributor, entered a court‑approved stipulation to issue 8,690,000 unregistered shares to Ironridge in satisfaction of ~ $687k of accounts payable, with an expressly disclosed price‑based adjustment mechanism permitting issuance of additional shares if Scrips’ share price declined during a calculation period.
- The stipulation and related disclosures explained the adjustment, warned of dilution, and stated the shares were freely tradable; Scrips and Ironridge jointly sought and obtained ex parte court approval in California state court.
- After issuance, Ironridge sold large quantities of Scrips stock on the open market; Scrips alleges Ironridge engaged in manipulative trading (so‑called “bid whacking” and other tactics) to depress the price and thereby increase the number of shares payable under the adjustment formula.
- Ironridge moved to dismiss Scrips’ federal securities claim (Rule 10b‑5) and sought dismissal/stay of state claims; the district court previously stayed state claims under Colorado River and twice permitted Scrips to amend its federal pleading.
- The second amended complaint appended voluminous trading data and an expert analysis; the court reviewed those trade records, the stipulation, SEC filings, and an SEC administrative order concerning Ironridge.
- The court found Scrips failed to plead (a) particularized manipulative acts, (b) actionable misrepresentations/omissions reasonably relied on, and (c) facts giving rise to a strong inference of scienter; it dismissed the Rule 10b‑5 claim with prejudice and declined supplemental jurisdiction over the state claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether SAC adequately pleads market manipulation under Rule 10b‑5 | Ironridge engaged in manipulative trading (bid whacking, sales >10% daily volume) to depress price and trigger adjustment | Trading data show Ironridge’s sales were within market ranges; raw data alone do not identify manipulative acts or who directed them | Dismissed: manipulation not pleaded with the required particularity; trades align with market activity and do not plausibly show manipulation |
| Whether Scrips pleaded actionable misrepresentations/omissions or promissory fraud | Ironridge promised not to manipulate and failed to disclose material facts (e.g., trading practices) | Stipulation fully disclosed adjustment and risks; merger clause and admissions negate reliance on prior oral promises | Dismissed: no adequately pleaded misrepresentation/omission; promissory fraud unsupported because nonperformance alone is insufficient and intent not pleaded with particulars |
| Whether Scrips adequately alleged reliance (actual or presumptive) | Reliance on assumption market was free of manipulation; alternatively, invoke presumptions (Affiliated Ute/fraud‑on‑the‑market) | Merger clause, disclosures, and Scrips’ own admission of being advised preclude justifiable reliance; OTC trading and facts do not support market efficiency needed for fraud‑on‑the‑market | Dismissed: reliance not plausibly alleged; neither omission presumption nor fraud‑on‑the‑market applies |
| Whether scienter pleaded with the PSLRA’s heightened standard | Pattern of similar transactions, SEC materials, and trading conduct show intent to manipulate | Alleged pattern evidence is hearsay/unspecified; SEC order does not allege manipulation; disclosed transaction terms undermine inference of intent to defraud | Dismissed with prejudice: scienter not established; holistic review favors nonfraudulent inferences |
Key Cases Cited
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (PSLRA scienter inference standard)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (plausibility standard for pleadings)
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading requirements; legal conclusions insufficient)
- ATSI Communications, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (manipulation pleading principles; relaxed particularity for manipulation claims in some contexts)
- Zucco Partners, LLC v. Digimarc Corp., 552 F.3d 981 (Ninth Circuit on PSLRA scienter pleading and holistic review)
- Basic Inc. v. Levinson, 485 U.S. 224 (fraud‑on‑the‑market presumption)
- Chiarella v. United States, 445 U.S. 222 (no duty to disclose absent special relationship)
- Santa Fe Industries, Inc. v. Green, 430 U.S. 462 (manipulation requires acts intended to mislead investors)
- Ernst & Ernst v. Hochfelder, 425 U.S. 185 (scienter defined as intent to deceive, manipulate, or defraud)
- Paracor Financial, Inc. v. General Electric Capital Corp., 96 F.3d 1151 (reliance and contractual merger clauses affecting fraud claims)